Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. DN typically manifests by glomerular hyperfiltration and microalbuminuria; then, the disease progresses to impaired glomerular filtration rate, which leads to ESRD. Treatment options for DN include the strict control of blood glucose levels and pressure (e.g., intraglomerular hypertension). However, the search for novel therapeutic strategies is ongoing. These include seeking specific molecules that contribute to the development and progression of DN to potentially interfere with these “molecular targets” as well as with the cellular targets within the kidney such as podocytes, which play a major role in the pathogenesis of DN. Recently, podocyte membrane protein urokinase receptor (uPAR) and its circulating form (suPAR) are found to be significantly induced in glomeruli and sera of DN patients, respectively, and elevated suPAR levels predicted diabetic kidney disease years before the occurrence of microalbuminuria. The intent of this review is to summarize the emerging evidence of uPAR and suPAR in the clinical manifestations of DN. The identification of specific pathways that govern DN will help us build a more comprehensive molecular model for the pathogenesis of the disease that can inform new opportunities for treatment.
National Institute of Diabetes and Digestive and Kidney DiseasesR01DK106051R01DK101350
Diabetes mellitus (DM) is a disorder of glucose metabolism that occurs due to either defect in insulin production by the pancreatic beta cells (type 1 DM) or resistance to insulin in the peripheral tissues (type 2 DM). With the increasing prevalence in obesity and metabolic syndrome, incidence of type 2 DM has been increasing worldwide, including the United States, where approximately 29.1 million people or 9.3% of the population are affected [1]. It is estimated that more than 400 million people will be affected with DM by 2030 [2]. Urinary albumin excretion ranging between 30 and 300 mg/24 h (microalbuminuria) is the earliest sign of diabetic kidney disease (DKD) [3]. Along with microalbuminuria, DN is also characterized by the increased levels of plasma creatinine and the decreased estimated glomerular filtration rate (eGFR) [4] since almost one third of type 2 diabetes patients have renal insufficiency without microalbuminuria [5]. This alone questions the assumption that microalbuminuria could be used as a marker rather than a predictor of DN [6]. Diabetic nephropathy (DN) is the major microvascular complication of diabetes and is one of the leading causes of end-stage renal disease (ESRD) affecting one third of all diabetic individuals in the United States [7]. Persistently high albumin excretion (≥300 mg/24 h), a condition known as macroalbuminuria, increases the chances of progressing to ESRD by 10 times compared to patients with normal urine albumin levels [8]. Many factors including diet, lifestyle, chronic blood glucose levels (HbA1C), blood pressure (BP), smoking, serum cholesterol, and genetic predisposition together play a crucial role in the progression of DN to ESRD.
Since the renin–angiotensin system (RAS) plays an important role in regulating systemic BP, blockade of its activation by either angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II type 1 receptor blockers (ARBs) are standard treatments for lowering the BP as well as slowing the progression of DN [9] and chronic renal failure [10]. Cumulative evidence has demonstrated that these first-line agents have represented a significant benefit in regard to partial renal protection in patients with diabetes and proteinuria [11–13]. However, antihypertensive therapy with RAS blockers contributes to the hyperkalemia (high potassium level in the blood) [14] especially when the patients treated with a combined therapy utilizing both an ACE inhibitor and an ARB together [15]. Other concerns of the RAS blockade include the potential long-term adverse effects and the need for dose optimization or individualization [16].
Recently, soluble urokinase receptor (suPAR) has been associated with podocytopathy, FSGS, and systemic levels of suPAR which are increased in patients with DM. Elevated suPAR levels predict incident chronic kidney disease also in patients with DM [17]. Furthermore, elevated suPAR in healthy people with predisposition for DM predicts microalbuminuria, an established early sign of DN by several years [18]. Podocytes have a major role in the pathogenesis of DN and its progression to ESRD [19, 20]. Podocytes are the important components of the glomerular filtration barrier that prevents the excretion of albumin into the urine [21]. These visceral epithelial cells of the glomerular tuft are a highly specialized structure containing a cell body, major processes that extend outward, and distal foot processes (FPs) that surround the glomerular capillaries [22]. Podocyte FPs are interconnected by a tiny multiprotein complex, slit diaphragm (SD), which regulates this active contractile structure ([23]). Podocytes sit on the glomerular basement membrane (GBM) [24], face the urinary space of Bowman’s capsule, and form a unique filtration apparatus by interdigitating with the neighboring FPs. GBM separates podocytes from the innermost component of the glomerular filtration, endothelial cells, which are perforated by pores (“fenestrae” or “fenestrations”) to enhance the permeability of water and small solutes while still restricting the free passage of cellular components of blood to Bowman’s (urinary) space [25]. Damage to the structural and functional components of podocytes results in the effacement of FPs (also referred to as “podocyte fusion” or “retraction”) and detachment of podocytes from the GBM causing the leak of serum proteins into the urine, a condition known as “proteinuria” [26, 27]. Proteinuria is a predictor of glomerular damage and hallmark of many renal disorders, including human and experimental DN. In various diabetic animal studies, it has been observed that there is podocyte hypertrophy (increase in the mean podocyte volume) [28, 29], cytoskeleton abnormalities [30, 31], and aberrant decrease in the density of podocytes [29, 32, 33]. Clinical studies were able to confirm the correlation between the podocyte loss and the disease progression in type 1 [34, 35] and type 2 diabetic patients [36–39] or in obesity-related glomerulopathy [40], which shares common pathophysiological factors relevant to glomerular damage with DN. Since podocytes have a limited capacity to divide [41], detached podocytes cannot be replaced by the adjacent podocytes; instead, surviving podocytes demonstrate an adaptation process called hypertrophy, where FPs of these residual podocytes enlarge to cover the surface of the glomerular capillary loops [22, 42]. Urinalysis of diabetic patients has shown that podocytes were seen in the urine of 53% and 80% of microalbuminuria and macroalbuminuria patients, respectively [43]. It should also be noted that podocytes remain viable after detachment and can be recovered in the urine pellets [44, 45]. Therefore, it comes as little surprise that podocytes are the key determinants of outcome for DKD and draw increased attention in diabetes research [46–51].
Owing to its complex architecture and dynamic movements, podocyte function is dependent on its abundantly rich actin cytoskeleton and ability to maintain diligently orchestrated interactions with the other members of the filtration barrier, that is, GBM and endothelial cells. The glomerular filtration barrier is permanently exposed to hydrostatic pressure gradient across the capillaries, and therefore, the integrity of the interaction between the podocytes and the GBM is essential for the filtration to occur. Podocytes, which are the most vulnerable components of the glomerular filtration, adhere to the underlying GBM via cell-matrix adhesion receptors, including α-dystroglycan; syndecan-4; type XVII collagen; integrins α3β1, α2β1, and αvβ3; and a variety of other linker, scaffolding, and signaling proteins [52]. Among those, integrin family of cell adhesion receptors are of significant interest since they facilitate the interaction of podocytes with the extracellular matrix (ECM) at focal adhesions (FAs) and, as a separate regulatory function, transduce signals to the inside of the podocytes (outside-in signaling) to activate intracellular signaling events [53, 54]. The latter happens upon interaction of integrins with their respective ligands such as fibronectin, vitronectin, collagen, and laminin. This ligand binding process is not strictly receptor-specific, that is, each of these cell adhesion proteins can bind to more than one type of integrin. This receptor versatility generates a venue for a wide variety of intracellular signals required for development, growth, proliferation, differentiation, motility, cellular metabolism, and survival. In order to propagate intracellular signaling cascades, integrins need to connect actin cytoskeleton by recruiting a small repertoire of linker proteins such as paxillin, talin, vinculin, and α-actinin [55, 56] as the short cytoplasmic tails of these multi-subunit proteins lack actin-binding capacity [57], the only exception being integrin β4, which has ~1000 amino acids in its cytoplasmic tail (compared to that of a typical integrin β subunit, which is less than 75 amino acids long) and connects to the keratin cytoskeleton specifically [58]. The interaction with the adaptor proteins is mainly regulated by β subunits, whereas α subunits usually mediate the binding to ECM [59]. Given the emphasis on signaling, it is anticipated that integrins undergo significant conformational changes upon intracellular signaling leading to “integrin activation” that alters its ligand binding activity (inside-out signaling) [60, 61]. This mechanism highlights the bidirectional control of integrins’ signaling [57, 62].
In humans, 24 αβ transmembrane heterodimers have been identified, making the integrin superfamily one of the most structurally diverse molecules of cell adhesion [63, 64]. α3β1 is the most highly expressed integrin in the kidney and the major regulator of the cell-matrix adhesion in podocytes [65, 66]. Mice deficient of α3β1 integrin failed to have the normal network of FPs; instead, displayed flattened podocyte processes that were still attached to GBM leading to decreased capillary loop formation [67] suggesting that α3β1 is needed for the proper rearrangement of podocyte cytoskeleton. A recent study showed that integrin α3β1 expression was upregulated in podocytes of patients with early DN [68] as opposed to the previous findings reporting a decrease in α3β1 expression in podocytes cultured under high-glucose conditions [69, 70] as well as in podocytes of animal models of DN [71–73] and DN patients [72]. On the other hand, expression of another member of integrin family, αvβ3, increases in the setting of DN [74–76]. Taken together, these papers present a panoramic picture suggestive of the contribution of altered interaction of podocytes with GBM proteins to diabetic renal pathology. Major gaps in our understanding remain, particularly the molecular mechanisms by which hyperglycemia suppresses or upregulates the expression of these transmembrane receptors.
Our group recently reported that the β3 subunit of integrin was essential for the action of podocyte membrane protein urokinase plasminogen activator receptor (uPAR), which eventually led to effacement of the FPs and proteinuria [77]. uPAR lacks transmembrane and intracellular domains, and it is associated with the external surface of the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor [78]. uPAR regulates the plasminogen activation system by binding urokinase (uPA) and its zymogen form, pro-UPA [79]. The ECM protein vitronectin is another immediate binding partner of uPAR and interacts with integrin coreceptors to activate integrin signaling and promote cell–ECM interactions [80, 81]. The resulting changes in expression or regulation of ECM receptors further instigate downstream signaling events that facilitate cell migration through activation of Rho family small GTPase Rac1 [77, 82, 83]. Interestingly, uPAR is not expressed in normal kidneys [84], and both uPA and uPAR expression is significantly upregulated in kidney cortex [85] and in all types of glomerular cells including podocytes [86, 87] in the animal models of DN.
Cell surface uPAR can be shed by several proteases, leaving it devoid of the GPI anchor, to generate a soluble form of uPAR (suPAR) [88, 89]. suPAR is a stable three-domain (D1, D2, and D3) protein that retains most of uPAR activities; both uPAR and suPAR are involved in the cell attachment, motility, and migration through their interaction with the integrins [90, 91]. Further cleavage through the linker connecting D1 and D2 domains generates a soluble D1 fragment and the residual D2-D3 fragment, which may remain membrane-bound or detach from the membrane [92, 93]. suPAR circulates in blood and other body fluids and has been identified in various pathological conditions: elevated plasma suPAR levels are predictive of cancer [94–96], cardiovascular disease (CVD) [94, 97–99], chronic kidney disease (CKD) [17], and type 1 [100] and type 2 diabetes [94, 101, 102]. In patients with type 2 DM, suPAR levels are increased with decreasing GFR, increasing proteinuria and can be a potential biomarker for staging of DN in type 2 DM patients [103]. Serum suPAR levels are also elevated in type 1 diabetic patients with DKD [104]. RAS blockade is an established treatment shown to decrease the progression of DN. Diabetic rats treated with ACEI resulted in inhibition of expression of uPAR in the kidneys [86]. In a randomized control study, RAS blockade in patients with DN showed decreased urinary suPAR levels compared to the group treated with placebo, but no difference is found in the plasma suPAR levels between the two groups [105]. This indicates that RAS blockade might decrease the renal suPAR production in vivo and can be the reason for decreased urinary suPAR levels in the treatment group compared to the placebo. With suPAR affecting the structure and functional aspects of podocytes resulting in FP effacement and proteinuria as well as decrease in the urinary level of suPAR by the treatment of renoprotective drugs like RAS blockers, there is a possibility that suPAR might have a major role in the pathogenesis and progression of DN. It remains to be determined what is the mechanism by which suPAR exerts its pathologic effects.
Our studies have demonstrated that, in LPS-treated mice, suPAR activates integrin αvβ3 present on podocyte cell membrane in a similar manner to uPAR [77] and results in the podocyte FP effacement and podocyte migration leading to glomerular focal segmental glomerulosclerosis (FSGS) and proteinuria [106]. We recently reported that suPAR also activates integrin αvβ3 when added to cultured human podocytes either in the form of suPAR-rich FSGS patient sera [106] or as a recombinant protein [104]. Of note, the pathological suPAR is originating from the bone marrow (BM) Gr-1lo immature myeloid cells [107]. The suPAR-mediated podocyte injury can be prevented if suPAR activity is blocked by an uPAR-specific monoclonal antibody or by a small molecule that blocks β3 integrin activity, cycloRGDfV. It has been reported that efforts to inhibit uPA-uPAR protein interaction with a small molecule promotes conformational states of uPAR and weakens or even inhibits its interaction with vitronectin, a ligand of β3 integrin [108]. The functional relationship between αvβ3 and uPAR/suPAR can also be interfered by acid sphingomyelinase-like phosphodiesterase 3b (SMPDL-3b) in the setting of DKD, where αvβ3 integrin is not activated in the presence of high suPAR and increased SMPDL-3b, but the differential expression of these proteins rather causes podocyte motility and apoptosis [104]. Recently, blocking αvβ3 integrin ligand occupancy by a monoclonal antibody that binds to β3 subunit of αvβ3 integrin has been offered as a potential solution to prevent and reverse proteinuria associated with hyperglycemia in back-to-back studies [109, 110]. In these studies, it has been shown that targeting αvβ3 with the monoclonal antibody alleviated several histological changes associated with DN in hyperglycemic pigs [109] and resulted in the reversal of proteinuria and inhibition of the synthesis of DN-related proteins in diabetic rat kidneys [110]. In the earlier related in vitro studies, the same group found out that the inhibition of ligand occupancy of αvβ3 inhibited pathophysiologic (i.e., proliferative or migratory) responses of retinal endothelial [111], vascular endothelial, and smooth muscle cells [112] through a series of signaling pathways stimulated by insulin-like growth factor 1 (IGF-1) when the cells are exposed to the high glucose. Knowing that αvβ3 integrin receptors are expressed in glomerular endothelium [75], similar events might occur in the glomeruli leading to endothelial permeability and proteinuria, which can be reversed by blocking αvβ3 integrin.
In a recent prospective long-term cohort study of patients at risk for type 2 diabetes, it has been observed that higher baseline suPAR is independently associated with an increased risk of new-onset microalbuminuria and prediabetes [18]. The association of suPAR with incident microalbuminuria was reported to be independent from baseline eGFR. Importantly, the onset of microalbuminuria preceded the decline in GFR in this cohort. Moreover, suPAR predicted microalbuminuria irrespective of the baseline blood pressure and glycemia (e.g., baseline HbA1c). By these results, it can be hypothesized that suPAR can be an upstream biomarker for type 2 diabetes and also for DN even before the microalbuminuria. In another cross sectional study of patients with manifest type 2 diabetes, higher suPAR level is associated with high urinary albumin indicating that suPAR might be involved in the pathogenesis and progression of DN [18].
Overall, the transmembrane partnership between uPAR/suPAR and αvβ3 integrin (as summarized in Figure 1) is an attractive target for the treatment of DKD. There are numerous studies dedicated to identify novel therapies efficiently targeting this delicate interaction with the use of antibodies, peptides, and small molecules. These efforts improve our understanding of the mechanism behind DN and our ability to predict the incidence of diabetic kidney disease (Figure 2), which will eventually advance the use of these agents toward clinical practice.
Schematic depiction of uPAR/suPAR-αvβ3 integrin signaling at the glomerular filtration level in health and diabetic disease. In resting podocytes, uPAR interacts with uPA and anchored to the outer plasma membrane with GPI. This complex is connected to αvβ3 integrin through vitronectin, a β3 integrin ligand. This leads to the initiation of “outside-in” signaling events, which requires the recruitment of linker proteins (paxillin, talin, and vinculin) by integrins for actin involvement. This signaling pathway is responsible for proper actin cytoskeleton assembly, lamellipodia formation, growth, proliferation, differentiation, and cell survival. ECM proteins such as fibronectin, collagen, and laminin are also involved in many cellular activities including ECM organization, cell adhesion and migration. Three homologous domains of uPAR are denoted by D1, D2, and D3, respectively (left panel). In the hyperglycemic state, αvβ3 integrin activity increases causing altered adhesion, migration, and proliferation. These intracellular changes might initiate an “inside-out” signaling affecting integrin’s binding affinity. Soluble uPAR also increases in circulation and probably contributes to the pathology of the diabetic kidney disease, which can be characterized as impaired cytoskeletal organization and podocyte FP effacement. The pathogenic suPAR is mainly generated by bone marrow-immature myeloid cells. Podocyte-specific expression of SMPDL-3b, which is elevated during the course of diabetic kidney disease, prevents αvβ3 integrin activation by interacting with suPAR. This eventually increases RhoA activity and podocyte susceptibility to apoptosis. αvβ3 integrin receptors are also expressed in glomerular endothelium and exposure of endothelial cells to hyperglycemia leads to pathologic outcomes in these cells such as endothelial permeability, migration, and proliferation in response to the ligand occupancy of αvβ3 and concomitant stimulation of IGF-1 (middle panel). Targeting uPAR and suPAR with an uPAR-specific monoclonal antibody can attenuate the adverse effects of uPAR/suPAR-dependent integrin signaling. Using antibodies that bind preferentially to the activated and/or ligand-occupied forms of β3 integrin and β3 integrin small molecule inhibitor, cycloRGDfV, offer alternative ways to disentangle its interactions with uPAR/suPAR. Blocking the ligand occupancy of αvβ3 inhibits the pathogenic mechanisms stimulated by IGF-1 (right panel).
Schematic depiction of suPAR as a predictor for future diabetic kidney disease.
Conflicts of Interest
Ranadheer R. Dande, Vasil Peev, and Mehmet M. Altintas declare that they have no conflict of interest. Jochen Reiser is the cofounder of TRISAQ, a biotech company dedicated to develop novel therapies for renal disease. He stands to gain royalties for commercialization of these products.
Acknowledgments
The work in Jochen Reiser’s laboratory is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grants R01DK101350 and R01DK106051.
SatirapojB.AdlerS. G.Prevalence and management of diabetic nephropathy in Western countries201511617010.1159/000382028ChenL.MaglianoD. J.ZimmetP. Z.The worldwide epidemiology of type 2 diabetes mellitus - present and future perspectives2012842282362206449310.1038/nrendo.2011.1832-s2.0-84858702540MogensenC. E.Microalbuminuria as a predictor of clinical diabetic nephropathy198731267368910.1038/ki.1987.5035502390023134379EknoyanG.HostetterT.BakrisG. L.HebertL.LeveyA. S.ParvingH. H.SteffesM. W.TotoR.Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK)200342461762210.1016/S0272-6386(03)00826-62-s2.0-0141819203145206120141819203KramerH. J.NguyenQ. D.CurhanG.HsuC. Y.Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus2003289243273327710.1001/jama.289.24.32732-s2.0-0038506499128242080038506499CaramoriM. L.FiorettoP.MauerM.The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?20004991399140810.2337/diabetes.49.9.1399109698210033850165de BoerI. H.RueT. C.HallY. N.HeagertyP. J.WeissN. S.HimmelfarbJ.Temporal trends in the prevalence of diabetic kidney disease in the United States2011305242532253910.1001/jama.2011.8612-s2.0-799594875862169374179959487586GersteinH. C.MannJ. F.YiQ.ZinmanB.DinneenS. F.HoogwerfB.HalleJ. P.YoungJ.RashkowA.JoyceC.NawazS.YusufS.Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals2001286442142610.1001/jama.286.4.421American Diabetes AssociationStandards of medical care in diabetes—2012201235Supplement 1S11S632218746910.2337/dc12-s0112-s2.0-84855185039TalerS. J.AgarwalR.BakrisG. L.FlynnJ. T.NilssonP. M.RahmanM.SandersP. W.TextorS. C.WeirM. R.TownsendR. R.KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD201362220121310.1053/j.ajkd.2013.03.0182-s2.0-848806449102368414584880644910LewisE. J.HunsickerL. G.BainR. P.RohdeR. D.The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group19933292014561462LewisE. J.HunsickerL. G.ClarkeW. R.BerlT.PohlM. A.LewisJ. B.RitzE.AtkinsR. C.RohdeR.RazI.Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes20013451285186010.1080/00140139.2017.131345628361563BrennerB. M.CooperM. E.de ZeeuwD.KeaneW. F.MitchW. E.ParvingH. H.RemuzziG.SnapinnS. M.ZhangZ.ShahinfarS.RENAAL Study InvestigatorsEffects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy20013451286186910.1056/NEJMoa0111612-s2.0-0035922441115655180035922441PalmerB. F.Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system2004351658559210.1056/NEJMra0352792-s2.0-3442888821152950513442888821YamoutH.LazichI.BakrisG. L.Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease201421328128610.1053/j.ackd.2014.03.0052-s2.0-848995001282478045684899500128MajewskiC.BakrisG. L.Has RAAS blockade reached its limits in the treatment of diabetic nephropathy?201616424HayekS. S.SeverS.KoY. A.TrachtmanH.AwadM.WadhwaniS.AltintasM. M.WeiC.HottonA. L.FrenchA. L.SperlingL. S.LerakisS.QuyyumiA. A.ReiserJ.Soluble urokinase receptor and chronic kidney disease2015373201916192510.1056/NEJMoa15063622-s2.0-849468882502653983584946888250GuthoffM.WagnerR.RandrianarisoaE.HatziagelakiE.PeterA.HäringH. U.FritscheA.HeyneN.Soluble urokinase receptor (suPAR) predicts microalbuminuria in patients at risk for type 2 diabetes mellitus201774062710.1038/srep406272809155885009787674EstacioR. O.SchrierR. W.Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression20014635940811147259LinJ. S.SusztakK.Podocytes: the weakest link in diabetic kidney disease?201616545ReiserJ.AltintasM. M.Podocytes20165114(F1000 Faculty Rev)10.12688/f1000research.7255.12-s2.0-8496451071526918173PavenstädtH.KrizW.KretzlerM.Cell biology of the glomerular podocyte200383125330710.1055/s-0033-13496332-s2.0-8488831680924254344ReiserJ.KrizW.KretzlerM.MundelP.The glomerular slit diaphragm is a modified adherens junction20001111810616834FarquharM. G.The glomerular basement membrane: not gone, just forgotten200611682090209310.1172/JCI294882-s2.0-337467704771688605733746770477ObeidatM.ObeidatM.BallermannB. J.Glomerular endothelium: a porous sieve and formidable barrier2012318996497210.1016/j.yexcr.2012.02.0322-s2.0-848598262862246548084859826286MundelP.ShanklandS. J.Podocyte biology and response to injury200213123005301512444221MundelP.ReiserJ.Proteinuria: an enzymatic disease of the podocyte?201077757158010.1038/ki.2009.4242-s2.0-779495417461992410177949541746KimN. H.Podocyte hypertrophy in diabetic nephropathy200510Supplement 2141610.1093/ehjcvp/pvw04028363205HerbachN.SchairerI.BlutkeA.KautzS.SiebertA.GökeB.WolfE.WankeR.Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis20092964F819F829ZhouX.HurstR. D.TempletonD.WhitesideC. I.High glucose alters actin assembly in glomerular mesangial and epithelial cells19957333723837564270FiorinaP.VerganiA.BassiR.NiewczasM. A.AltintasM. M.PezzolesiM. G.D'AddioF.ChinM.TezzaS.Ben NasrM.MattinzoliD.IkehataM.CorradiD.SchumacherV.BuvallL.YuC. C.ChangJ. M.La RosaS.FinziG.SoliniA.VincentiF.RastaldiM. P.ReiserJ.KrolewskiA. S.MundelP. H.SayeghM. H.Role of podocyte B7-1 in diabetic nephropathy201425714151429SusztakK.RaffA. C.SchifferM.BöttingerE. P.Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy2006551225233GödelM.HartlebenB.HerbachN.LiuS.ZschiedrichS.LuS.Debreczeni-MórA.LindenmeyerM. T.RastaldiM. P.HartlebenG.WiechT.FornoniA.NelsonR. G.KretzlerM.WankeR.PavenstädtH.KerjaschkiD.CohenC. D.HallM. N.RüeggM. A.InokiK.WalzG.HuberT. B.Role of mTOR in podocyte function and diabetic nephropathy in humans and mice201112162197220910.1172/JCI447742-s2.0-799578814252160659179957881425SteffesM. W.SchmidtD.McCreryR.BasgenJ. M.Glomerular cell number in normal subjects and in type 1 diabetic patients20015962104211310.1046/j.1523-1755.2001.00725.x113808120035008793ToyodaM.NajafianB.KimY.CaramoriM. L.MauerM.Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy20075682155216010.2337/db07-00192-s2.0-345476119031753606434547611903PagtalunanM. E.MillerP. L.Jumping-EagleS.NelsonR. G.MyersB. D.RennkeH. G.CoplonN. S.SunL.MeyerT. W.Podocyte loss and progressive glomerular injury in type II diabetes199799234234810.1172/JCI11916390060030031029379MeyerT. W.BennettP. H.NelsonR. G.Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria199942111341134410.1007/s0012500514472-s2.0-0032710966105504180032710966WhiteK. E.BilousR. W.Diabetes Study GroupStructural alterations to the podocyte are related to proteinuria in type 2 diabetic patients20041961437144010.1093/ndt/gfh1292-s2.0-2942720686149934942942720686WeilE. J.LemleyK. V.MasonC. C.YeeB.JonesL. I.BlouchK.LovatoT.RichardsonM.MyersB. D.NelsonR. G.Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy20128291010101710.1038/ki.2012.2342-s2.0-848675768162271818984867576816ChenH. M.LiuZ. H.ZengC. H.LiS. J.WangQ. W.LiL. S.Podocyte lesions in patients with obesity-related glomerulopathy200648577277910.1053/j.ajkd.2006.07.0252-s2.0-337500597661705999633750059766LasagniL.LazzeriE.ShanklandS. J.AndersH. J.RomagnaniP.Podocyte mitosis - a catastrophe2013131132310.2174/1566524138044862502317614784878425128LiapisH.RomagnaniP.AndersH. J.New insights into the pathology of podocyte loss: mitotic catastrophe201318351364137410.1016/j.ajpath.2013.06.0332-s2.0-848866810742400788384886681074NakamuraT.UshiyamaC.SuzukiS.HaraM.ShimadaN.EbiharaI.KoideH.Urinary excretion of podocytes in patients with diabetic nephropathy20001591379138310.1093/ndt/15.9.1379109783940033833789VogelmannS. U.NelsonW. J.MyersB. D.LemleyK. V.Urinary excretion of viable podocytes in health and renal disease20032851F40F4810.1152/ajprenal.00404.2002126315530038045430PetermannA. T.PippinJ.KrofftR.BlonskiM.GriffinS.DurvasulaR.ShanklandS. J.Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis2004984e114e12310.1159/0000815552-s2.0-112442582911562779411244258291Dalla VestraM.MasieroA.RoiterA. M.SallerA.CrepaldiG.FiorettoP.Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes20035241031103510.2337/diabetes.52.4.10312-s2.0-0037381607126634760037381607WolfG.ChenS.ZiyadehF. N.From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy20055461626163410.2337/diabetes.54.6.16262-s2.0-200443622391591978220044362239ReddyG. R.KotlyarevskaK.RansomR. F.MenonR. K.The podocyte and diabetes mellitus: is the podocyte the key to the origins of diabetic nephropathy?2008171323610.1097/MNH.0b013e3282f2904d2-s2.0-373491207351809066737349120735BrosiusF. C.CowardR. J.Podocytes, signaling pathways, and vascular factors in diabetic kidney disease201421330431010.1053/j.ackd.2014.03.0112-s2.0-848995852412478045984899585241CowardR.FornoniA.Insulin signaling: implications for podocyte biology in diabetic kidney disease201524110411010.1097/MNH.00000000000000782-s2.0-849187694782541561784918769478MajumderS.AdvaniA.The epigenetic regulation of podocyte function in diabetes20152981337134410.1016/j.jdiacomp.2015.07.0152-s2.0-849487101352634472684948710135SachsN.SonnenbergA.Cell-matrix adhesion of podocytes in physiology and disease20139420021010.1038/nrneph.2012.2912-s2.0-848757021582333821184875702158HamerskiD. A.SantoroS. A.Integrins and the kidney: biology and pathobiology19998191410.1097/00041552-199901000-000032-s2.0-003291589299148550032915892MathewS.ChenX.PozziA.ZentR.Integrins in renal development201227689190010.1007/s00467-011-1890-12-s2.0-848639817152160390984863981715DelonI.BrownN. H.Integrins and the actin cytoskeleton2007191435010.1016/j.ceb.2006.12.0132-s2.0-338463097011718498533846309701WolfensonH.LavelinI.GeigerB.Dynamic regulation of the structure and functions of integrin adhesions201324544745810.1016/j.devcel.2013.02.0122-s2.0-848752737882348485284875273788HynesR. O.Integrins: bidirectional, allosteric signaling machines20021106673687de PeredaJ. M.WicheG.LiddingtonR. C.Crystal structure of a tandem pair of fibronectin type III domains from the cytoplasmic tail of integrin α6β4199918154087409510.1093/emboj/18.15.40872-s2.0-0033517122104289480033517122Vicente-ManzanaresM.ChoiC. K.HorwitzA. R.Integrins in cell migration – the actin connection2009122Part 2199206GinsbergM. H.PartridgeA.ShattilS. J.Integrin regulation200517550951610.1016/j.ceb.2005.08.0102-s2.0-246444776681609963624644477668LuoB. H.CarmanC. V.SpringerT. A.Structural basis of integrin regulation and signaling20072561964710.1146/annurev.immunol.25.022106.1416182-s2.0-342478915061720168134247891506KimM.CarmanC. V.SpringerT. A.Bidirectional transmembrane signaling by cytoplasmic domain separation in integrins200330156401720172510.1126/science.10841742-s2.0-0042681786145009820042681786ShimaokaM.TakagiJ.SpringerT. A.Conformational regulation of integrin structure and function20023148551610.1146/annurev.biophys.31.101101.1409222-s2.0-0036089390119884790036089390TakadaY.YeX.SimonS.The integrins20078521510.1186/gb-2007-8-5-2152-s2.0-345488268241754313634548826824KorhonenM.YlanneJ.LaitinenL.VirtanenI.The α1-α6 subunits of integrins are characteristically expressed in distinct segments of developing and adult human nephron199011131245125410.1083/jcb.111.3.12452-s2.0-002507679121440000025076791SterkL. M.de MelkerA. A.KramerD.KuikmanI.ChandA.ClaessenN.WeeningJ. J.SonnenbergA.Glomerular extracellular matrix components and integrins199853177192KreidbergJ. A.DonovanM. J.GoldsteinS. L.RennkeH.ShepherdK.JonesR. C.JaenischR.Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis199612211353735478951069SawadaK.ToyodaM.KaneyamaN.ShiraiwaS.MoriyaH.MiyatakeH.TanakaE.YamamotoN.MiyauchiM.KimuraM.WadaT.FukagawaM.Upregulation of α3β1-integrin in podocytes in early-stage diabetic nephropathy20162016926507410.1155/2016/92650742-s2.0-8497529285927340677KitsiouP. V.TziniaA. K.Stetler-StevensonW. G.MichaelA. F.FanW. W.ZhouB.TsilibaryE. C.Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells20032844F671F67910.1152/ajprenal.00266.2002126209210037376726ChenJ.GuiD.ChenY.MouL.LiuY.HuangJ.Astragaloside IV improves high glucose-induced podocyte adhesion dysfunction via alpha3beta1 integrin upregulation and integrin-linked kinase inhibition200876679680410.1016/j.bcp.2008.06.0202-s2.0-506490926541865280450649092654RegoliM.BendayanM.Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus1997401152210.1007/s0012500506372-s2.0-003103355790287130031033557ChenH. C.ChenC. A.GuhJ. Y.ChangJ. M.ShinS. J.LaiY. H.Altering expression of α3β1 integrin on podocytes of human and rats with diabetes200067192345235310.1016/S0024-3205(00)00815-82-s2.0-0034730249110651810034730249LinS.LiD.JiaJ.ZhengZ.JiaZ.ShangW.Spironolactone ameliorates podocytic adhesive capacity via restoring integrin α3 expression in streptozotocin-induced diabetic rats201011314915710.1177/14703203103696032-s2.0-7795629797420525748BoettigerD.Enomoto-IwamotoM.YoonH. Y.HoferU.MenkoA. S.Chiquet-EhrismannR.Regulation of integrin α5β1 affinity during myogenic differentiation1995169126127210.1006/dbio.1995.11422-s2.0-002899000875384770028990008JinD. K.FishA. J.WaynerE. A.MauerM.SettyS.TsilibaryE.KimY.Distribution of integrin subunits in human diabetic kidneys1996712263626458989742YoonS.GingrasD.BendayanM.Alterations of vitronectin and its receptor α(v) integrin in the rat renal glomerular wall during diabetes20013861298130610.1053/ajkd.2001.29228117289640035720014WeiC.MöllerC. C.AltintasM. M.LiJ.SchwarzK.ZacchignaS.XieL.HengerA.SchmidH.RastaldiM. P.CowanP.KretzlerM.ParrillaR.BendayanM.GuptaV.NikolicB.KalluriR.CarmelietP.MundelP.ReiserJ.Modification of kidney barrier function by the urokinase receptor2008141556310.1038/nm16962-s2.0-38049032013PlougM.RonneE.BehrendtN.JensenA. L.BlasiF.DanoK.Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol19912663192619331846368EllisV.BehrendtN.DanoK.Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor19912661912752127581829461WeiY.LukashevM.SimonD. I.BodaryS. C.RosenbergS.DoyleM. V.ChapmanH. A.Regulation of integrin function by the urokinase receptor199627352811551155510.1126/science.273.5281.155187032170029764639MadsenC. D.FerrarisG. M. S.AndolfoA.CunninghamO.SideniusN.uPAR-induced cell adhesion and migration: vitronectin provides the key2007177592793910.1083/jcb.2006120582-s2.0-342498703631754851634249870363KjollerL.HallA.Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin200115261145115810.1083/jcb.152.6.11452-s2.0-0035911966112571160035911966SmithH. W.MarraP.MarshallC. J.uPAR promotes formation of the p130Cas-CRK complex to activate Rac through DOCK1802008182477779010.1083/jcb.2007120502-s2.0-502491456971872554150249145697XuY.HagegeJ.MougenotB.SraerJ. D.RonneE.RondeauE.Different expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney19965062011201910.1038/ki.1996.52389434840029903407VasirB.ReitzP.XuG.SharmaA.Bonner-WeirS.WeirG. C.Effects of diabetes and hypoxia on gene markers of angiogenesis (HGF, cMET, uPA and uPAR, TGF-alpha, TGF-beta, bFGF and vimentin) in cultured and transplanted rat islets200043676377210.1007/s001250051374109071220034095746KenichiM.MasanobuM.TakehikoK.ShokoT.AkiraF.KatsushigeA.TakashiH.YoshiyukiO.ShigeruK.Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor20041442697710.1016/j.lab.2004.04.0022-s2.0-4344578829153225014344578829ZhangL.LiR.ShiW.LiangX.LiuS.YeZ.YuC.ChenY.ZhangB.WangW.LaiY.MaJ.LiZ.TanX.NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice2013170242643910.1111/bph.122922-s2.0-848832557602382686484883255760SideniusN.SierC. F.BlasiF.Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo20004751525610.1016/S0014-5793(00)01624-02-s2.0-0034625509108548570034625509MontuoriN.CarrieroM. V.SalzanoS.RossiG.RagnoP.The cleavage of the urokinase receptor regulates its multiple functions200227749469324693910.1074/jbc.M2074942002-s2.0-0346736507122975050346736507HuaiQ.MazarA. P.KuoA.ParryG. C.ShawD. E.CallahanJ.LiY.YuanC.BianC.ChenL.FurieB.FurieB. C.CinesD. B.HuangM.Structure of human urokinase plasminogen activator in complex with its receptor2006311576165665910.1126/science.11211432-s2.0-319444470121645607931944447012ThunoM.MachoB.Eugen-OlsenJ.suPAR: the molecular crystal ball200927315717210.3233/DMA-2009-06572-s2.0-733491251151989321073349125115Hoyer-HansenG.RonneE.SolbergH.BehrendtN.PlougM.LundL. R.EllisV.DanoK.Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain19922672518224182291381366WahlbergK.Hoyer-HansenG.CasslenB.Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer19985815329432989699658Eugen-OlsenJ.AndersenO.LinnebergA.LadelundS.HansenT. W.LangkildeA.PetersenJ.PielakT.MollerL. N.JeppesenJ.LyngbaekS.FengerM.OlsenM. H.HildebrandtP. R.Borch-JohnsenK.JørgensenT.HaugaardS. B.Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population2010268329630810.1111/j.1365-2796.2010.02252.x2-s2.0-779552544542056114877955254454LangkildeA.HansenT. W.LadelundS.LinnebergA.AndersenO.HaugaardS. B.JeppesenJ.Eugen-OlsenJ.Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals201120460961810.1158/1055-9965.EPI-10-10092-s2.0-799557480402123968479955748040DonadelloK.ScollettaS.TacconeF. S.CovajesC.SantonocitoC.CortesD. O.GrazulyteD.GottinL.VincentJ. L.Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients201429114414910.1016/j.jcrc.2013.08.0052-s2.0-848901672782412008984890167278PerssonM.EngstromG.BjorkbackaH.HedbladB.Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study20122202502505LyngbaekS.MarottJ. L.SehestedtT.HansenT. W.OlsenM. H.AndersenO.LinnebergA.HaugaardS. B.Eugen-OlsenJ.HansenP. R.JeppesenJ.Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham risk score201316762904291110.1016/j.ijcard.2012.07.0182-s2.0-848837868782290941084883786878BorneY.PerssonM.MelanderO.SmithJ. G.EngstromG.Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation201416437738310.1002/ejhf.492-s2.0-849375667222446477784937566722TheiladeS.LyngbaekS.HansenT. W.Eugen-OlsenJ.FengerM.RossingP.JeppesenJ. L.Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes2015277336237110.1111/joim.122692-s2.0-849231081062483087384923108106HaugaardS. B.AndersenO.HansenT. W.Eugen-OlsenJ.LinnebergA.MadsbadS.OlsenM. H.JørgensenT.Borch-JohnsenK.JeppesenJ.The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men201229447948710.1111/j.1464-5491.2011.03513.x2-s2.0-848581856302205046284858185630HeraclidesA.JensenT. M.RasmussenS. S.Eugen-OlsenJ.HaugaardS. B.Borch-JohnsenK.SandbækA.LauritzenT.WitteD. R.The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status201356715421546WuC. Z.ChangL. C.LinY. F.HungY. J.PeiD.ChuN. F.ChenJ. S.Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy201548181324132910.1016/j.clinbiochem.2015.07.0012-s2.0-849491136892616249484949113689YooT. H.PedigoC. E.GuzmanJ.Correa-MedinaM.WeiC.VillarrealR.MitrofanovaA.LeclercqF.FaulC.LiJ.KretzlerM.NelsonR. G.LehtoM.ForsblomC.GroopP. H.ReiserJ.BurkeG. W.FornoniA.MerscherS.Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease2015261133147PerssonF.TheiladeS.Eugen-OlsenJ.RossingP.ParvingH. H.Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes20163081440144210.1016/j.jdiacomp.2016.07.0032-s2.0-849797715362747526284979771536WeiC.El HindiS.LiJ.FornoniA.GoesN.SageshimaJ.MaiguelD.KarumanchiS. A.YapH. K.SaleemM.ZhangQ.NikolicB.ChaudhuriA.DaftarianP.SalidoE.TorresA.SalifuM.SarwalM. M.SchaeferF.MorathC.SchwengerV.ZeierM.GuptaV.RothD.RastaldiM. P.BurkeG.RuizP.ReiserJ.Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis2011171895296010.1038/nm.24112-s2.0-799611329812180453979961132981HahmE.WeiC.FernandezI.LiJ.TardiN. J.TracyM.WadhwaniS.CaoY.PeevV.ZlozaA.LusciksJ.HayekS. S.O'ConnorC.BitzerM.GuptaV.SeverS.SykesD. B.ScaddenD. T.ReiserJ.Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease201723110010610.1038/nm.42422-s2.0-8500404505127941791LiuD.ZhouD.WangB.KnabeW. E.MerouehS. O.A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction20151061521153410.1021/cb500832q2-s2.0-849350353812567169484935035381MaileL. A.BusbyW. H.GollahonK. A.FlowersW.GarbacikN.GarbacikS.StewartK.NicholsT.BellingerD.PatelA.DunbarP.MedlinM.ClemmonsD.Blocking ligand occupancy of the αVβ3 integrin inhibits the development of nephropathy in diabetic pigs2014155124665467510.1210/en.2014-13182-s2.0-849110798232517159984911079823MaileL. A.GollahonK.WaiC.DunbarP.BusbyW.ClemmonsD.Blocking αVβ3 integrin ligand occupancy inhibits the progression of albuminuria in diabetic rats2014201442182710.1155/2014/4218272-s2.0-8491112714025389530MillerE. C.CappsB. E.SanghaniR. R.ClemmonsD. R.MaileL. A.Regulation of IGF-I signaling in retinal endothelial cells by hyperglycemia20074883878388710.1167/iovs.07-00142-s2.0-346488286841765276434648828684MaileL. A.CappsB. E.LingY.XiG.ClemmonsD. R.Hyperglycemia alters the responsiveness of smooth muscle cells to insulin-like growth factor-I200714852435244310.1210/en.2006-14402-s2.0-342497940181725520234249794018